Immunovia publ AB is a Sweden-based company engaged in the life science sector. The Company offers its services through its technology platform based on antibody microarray analysis, IMMray, which is dedicated to the diagnosis of cancer, to predicting disease progression and to monitoring the therapeutic responsiveness of cancers. The Company’s technology is designed not only for cancer but also for autoimmune diseases. The Company has its own antibody library, antibody production and purification, as well as its own chip/array production. The Company’s in-house recombinant antibody production and purification platform provides antibodies for microarray fabrication. The Company has on-going projects targeting other cancers, such as prostate cancer, as well as autoimmune diseases, such as systemic lupus erythematosus.